What CorMedix (CRMD)'s Dramatic Swing to Profitability and Raised Guidance Means for Shareholders

• On November 12, 2025, CorMedix Inc. reported a very large year-over-year increase in third quarter revenue to US$104.28 million and net income of US$108.56 million, while also issuing net revenue guidance of US$115 million to US$135 million for the fourth quarter ending December 31, 2025.
• This dramatic move from a net loss to a significant net profit highlights a sharp turnaround in the company’s operational and financial performance over the past year.
• We’ll examine how this transformation in quarterly profitability and forward guidance may impact CorMedix’s investment narrative and future outlook.

Find companies with promising cash flow potential yet trading below their fair value.

CorMedix Investment Narrative Recap

To own shares of CorMedix today, an investor must believe in the company’s ability to execute on its expanded hospital and anti-infective portfolio following its recent acquisition, and sustain strong operational performance in both the short and long term. The sharp move to profitability and increased revenue guidance are very positive for near-term execution, but do not materially reduce integration or regulatory risks, which remain significant for the business’s future trajectory.

Among recent announcements, the September 29 completion of enrollment for the Phase III ReSPECT trial of REZZAYO stands out, as success with this trial could significantly expand the product’s addressable market and reinforce investor confidence in upcoming catalysts. However, clinical and regulatory outcomes for new indications remain pivotal, with any setbacks potentially impacting the trajectory set by CorMedix’s robust quarterly results.

In contrast, one of the most important risks for investors to be aware of remains the challenge of integrating Melinta’s portfolio into CorMedix’s operations, and...

Read the full narrative on CorMedix (it's free!)

CorMedix's narrative projects $433.6 million revenue and $244.7 million earnings by 2028. This requires 52.8% yearly revenue growth and an earnings increase of $193.5 million from $51.2 million.

Uncover how CorMedix's forecasts yield a $20.40 fair value, a 79% upside to its current price.

Exploring Other Perspectives

Nine members of the Simply Wall St Community set fair value for CorMedix anywhere from US$7.48 to US$320.10 per share. With upcoming regulatory and clinical trial outcomes for new products, your outlook on growth and risk may be quite different from others in the market.

Explore 9 other fair value estimates on CorMedix - why the stock might be worth 35% less than the current price!

Build Your Own CorMedix Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CorMedix research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CorMedix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CorMedix's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com